These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38726878)

  • 61. Prognostic Indicators of Recurrence of Bacterial Vaginosis.
    Sobel JD; Kaur N; Woznicki NA; Boikov D; Aguin T; Gill G; Akins RA
    J Clin Microbiol; 2019 May; 57(5):. PubMed ID: 30842235
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus.
    Strandberg KL; Peterson ML; Lin YC; Pack MC; Chase DJ; Schlievert PM
    Antimicrob Agents Chemother; 2010 Feb; 54(2):597-601. PubMed ID: 20008774
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women.
    Marrazzo JM; Thomas KK; Fiedler TL; Ringwood K; Fredricks DN
    Ann Intern Med; 2008 Jul; 149(1):20-8. PubMed ID: 18591634
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A double-blind treatment study of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovules.
    Eriksson K; Carlsson B; Forsum U; Larsson PG
    Acta Derm Venereol; 2005; 85(1):42-6. PubMed ID: 15848990
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Vaginal retention of locally administered clindamycin.
    Eriksson K; Larsson PG; Nilsson M; Forsum U
    APMIS; 2011 Jun; 119(6):373-6. PubMed ID: 21569095
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Correlation Analysis of Vaginal Microbiome Changes and Bacterial Vaginosis Plus Vulvovaginal Candidiasis Mixed Vaginitis Prognosis.
    Xiao B; A D; Qin H; Mi L; Zhang D
    Front Cell Infect Microbiol; 2022; 12():860589. PubMed ID: 35372135
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vaginal microbiota molecular profiling and diagnostic performance of artificial intelligence-assisted multiplex PCR testing in women with bacterial vaginosis: a single-center experience.
    Lu S; Li Z; Chen X; Chen F; Yao H; Sun X; Cheng Y; Wang L; Dai P
    Front Cell Infect Microbiol; 2024; 14():1377225. PubMed ID: 38644962
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prevention of recurrence of bacterial vaginosis using lactobacilli-containing vaginal tablets among women with HIV: a randomized, placebo-controlled, double-blinded phase IV trial.
    Bangar S; Sonar P; Mane A; Sane S; Kadam A; Katendra TL; Rahane G; Sinha A; Sahay S
    Int J Infect Dis; 2023 Apr; 129():197-204. PubMed ID: 36773716
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rifaximin modulates the vaginal microbiome and metabolome in women affected by bacterial vaginosis.
    Laghi L; Picone G; Cruciani F; Brigidi P; Calanni F; Donders G; Capozzi F; Vitali B
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3411-20. PubMed ID: 24709255
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Composition of the vaginal microbiota in women of reproductive age--sensitive and specific molecular diagnosis of bacterial vaginosis is possible?
    Shipitsyna E; Roos A; Datcu R; Hallén A; Fredlund H; Jensen JS; Engstrand L; Unemo M
    PLoS One; 2013; 8(4):e60670. PubMed ID: 23585843
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Using an in-vitro biofilm model to assess the virulence potential of bacterial vaginosis or non-bacterial vaginosis Gardnerella vaginalis isolates.
    Castro J; Alves P; Sousa C; Cereija T; França Â; Jefferson KK; Cerca N
    Sci Rep; 2015 Jun; 5():11640. PubMed ID: 26113465
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The vaginal microbiota in the course of bacterial vaginosis treatment.
    Zwittink RD; van den Munckhof EHA; Leverstein-van Hall MA; Boers K; Molijn A; Knetsch CW; Kuijper EJ
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):651-656. PubMed ID: 33029765
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis.
    Sobel JD; Ferris D; Schwebke J; Nyirjesy P; Wiesenfeld HC; Peipert J; Soper D; Ohmit SE; Hillier SL
    Am J Obstet Gynecol; 2006 May; 194(5):1283-9. PubMed ID: 16647911
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis.
    Armstrong-Buisseret L; Brittain C; David M; Dean G; Griffiths F; Hepburn T; Jackson L; Kai J; Montgomery A; Roberts T; Thandi S; Ross JDC
    Trials; 2019 Nov; 20(1):648. PubMed ID: 31775859
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Evaluation of efficacy of ketoconazole 800 mg-clindamycin 100 mg tablets vaginal against ketoconazole 800 mg- clindamycin 100 mg vaginal capsules in candida vaginitis and vaginosis].
    Martínez-García A; Cejudo-Alvarez J; Bravo-Topete EG; Herrera-Villalobos JE; Garibay-Valencia M; Mirabent-González F
    Ginecol Obstet Mex; 2011 Feb; 79(2):75-85. PubMed ID: 21966787
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Testing the regulatory framework in South Africa - a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis.
    Happel AU; Singh R; Mitchev N; Mlisana K; Jaspan HB; Barnabas SL; Passmore JS
    BMC Infect Dis; 2020 Jul; 20(1):491. PubMed ID: 32650729
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vaginosis: Advances in new therapeutic development and microbiome restoration.
    Mohankumar B; Shandil RK; Narayanan S; Krishnan UM
    Microb Pathog; 2022 Jul; 168():105606. PubMed ID: 35644292
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The influence of sexual activity on the vaginal microbiota and Gardnerella vaginalis clade diversity in young women.
    Vodstrcil LA; Twin J; Garland SM; Fairley CK; Hocking JS; Law MG; Plummer EL; Fethers KA; Chow EP; Tabrizi SN; Bradshaw CS
    PLoS One; 2017; 12(2):e0171856. PubMed ID: 28234976
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Development of a microarray-based tool to characterize vaginal bacterial fluctuations and application to a novel antibiotic treatment for bacterial vaginosis.
    Cruciani F; Biagi E; Severgnini M; Consolandi C; Calanni F; Donders G; Brigidi P; Vitali B
    Antimicrob Agents Chemother; 2015 May; 59(5):2825-34. PubMed ID: 25733514
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of main lactobacillus species between healthy women and women with bacterial vaginosis.
    Yan DH; Lü Z; Su JR
    Chin Med J (Engl); 2009 Nov; 122(22):2748-51. PubMed ID: 19951608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.